Gelken Publishes Guide on Preventing Softgel Cross-Linking

Gelken, a supplier of pharmaceutical gelatin, has issued a technical guide aimed at pharmaceutical manufacturers, addressing the critical issue of gelatin cross-linking in softgel capsules. This phenomenon can significantly compromise product integrity and therapeutic efficacy.

Softgels are a preferred dosage form for delivering various active ingredients. However, cross-linking, where irreversible chemical bonds form between gelatin peptide chains, can cause the capsule shell to become insoluble. This leads to delayed dissolution, failed disintegration tests, and reduced bioavailability.

The guide identifies three primary causes for cross-linking: aldehyde interactions with gelatin, environmental stress from heat and humidity during manufacturing and storage, and impurities in excipients that can generate reactive compounds over time. These factors can lead to the formation of an insoluble pellicle during dissolution testing.

Gelken recommends several technical strategies for prevention. These include stringent control over gelatin raw material specifications, particularly minimizing iron and peroxide content. Manufacturers are also advised to optimize fill formulations to scavenge aldehydes and implement advanced drying systems that carefully control temperature and humidity to avoid thermal stress on the gelatin.

By managing these critical parameters, pharmaceutical companies can enhance the stability of their softgel products and ensure they meet regulatory standards throughout their shelf life.